Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A
lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Your browser is not supported
Switch to Chrome, Edge, Firefox or Safari
This brochure informs patients about buprenorphine and medication-assisted treatment for opioid use disorder. It describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.
Facts About Buprenorphine for Opioid Addiction
(PDF | 750 KB)
This poster lists five simple ways to reduce the risks of taking methadone for pain relief or medication-assisted treatment of opioid use disorders. It also offers suggested resources for additional information. The poster comes folded and is 11 inches x 15 inches.
This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.
This guide examines emerging and best practices for initiating medication-assisted treatment in emergency departments. It also reviews the existing literature and science of the topic, identifies gaps in knowledge, and discusses challenges of implementation.
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
This manual offers guidelines for medication-assisted treatment for people, particularly veterans, living with post-traumatic stress disorder and co-occurring opioid use disorders. It covers screening, concomitant treatment, pharmacotherapy, and multiple misused substances.
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
